Cargando…

Outpatient Blind Percutaneous Liver Biopsy in Infants and Children: Is it Safe?

BACKGROUND/AIM: We aim to investigate the safety of outpatient blind percutaneous liver biopsy (BPLB) in infants and children with chronic liver disease (CLD). PATIENTS AND METHODS: BPLB was performed as an outpatient procedure using the aspiration Menghini technique in 80 infants and children, aged...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Shabrawi, Mortada H., El-Karaksy, Hanaa M., Okahsa, Sawsan H., Kamal, Naglaa M., El-Batran, Gamal, Badr, Khaled A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271690/
https://www.ncbi.nlm.nih.gov/pubmed/22249089
http://dx.doi.org/10.4103/1319-3767.91735
_version_ 1782222749455876096
author El-Shabrawi, Mortada H.
El-Karaksy, Hanaa M.
Okahsa, Sawsan H.
Kamal, Naglaa M.
El-Batran, Gamal
Badr, Khaled A.
author_facet El-Shabrawi, Mortada H.
El-Karaksy, Hanaa M.
Okahsa, Sawsan H.
Kamal, Naglaa M.
El-Batran, Gamal
Badr, Khaled A.
author_sort El-Shabrawi, Mortada H.
collection PubMed
description BACKGROUND/AIM: We aim to investigate the safety of outpatient blind percutaneous liver biopsy (BPLB) in infants and children with chronic liver disease (CLD). PATIENTS AND METHODS: BPLB was performed as an outpatient procedure using the aspiration Menghini technique in 80 infants and children, aged 2 months to 14 yrs, for diagnosis of their CLD. Patients were divided into three groups: Group 1 (<1 year), group 2 (1–6 yrs), and group 3 (6–14 yrs). The vital signs were closely monitored 1 hr before biopsy, and then 1, 2, 6, and 24 hrs after biopsy. Twenty-four hours pre- and post-biopsy complete blood counts, liver enzymes, prothrombin time (PT), and abdominal ultrasonography, searching for a biopsy-induced hematoma, were done for all patients. RESULTS: No mortality or major morbidities were encountered after BPLB. The rate of minor complications was 17.5% including irritability or “pain” requiring analgesia in 10%, mild fever in 5%, and drowsiness for >6 hrs due to oversedation in 2.5%. There was a statistically significant rise in the 1-hr post-biopsy mean heart and respiratory rates, but the rise was non-significant at 6 and 24 hrs except for group 2 where heart rate and respiratory rates significantly dropped at 24 hrs. No statistically significant difference was noted between the mean pre-biopsy and the 1, 6, and 24-hrs post-biopsy values of blood pressure in all groups. The 24-hrs post-biopsy mean hemoglobin and hematocrit showed a significant decrease, while the 24-hrs post-biopsy mean total leucocyte and platelet counts showed non-significant changes. The 24-hrs post-biopsy mean liver enzymes were non-significantly changed except the 24-hrs post-biopsy mean PT which was found to be significantly prolonged, for a yet unknown reason(s). CONCLUSIONS: Outpatient BPLB performed by the Menghini technique is safe and well tolerated even in infants and young children. Frequent, close monitoring of patients is strongly recommended to achieve optimal patient safety and avoid potential complications.
format Online
Article
Text
id pubmed-3271690
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-32716902012-02-15 Outpatient Blind Percutaneous Liver Biopsy in Infants and Children: Is it Safe? El-Shabrawi, Mortada H. El-Karaksy, Hanaa M. Okahsa, Sawsan H. Kamal, Naglaa M. El-Batran, Gamal Badr, Khaled A. Saudi J Gastroenterol Original Article BACKGROUND/AIM: We aim to investigate the safety of outpatient blind percutaneous liver biopsy (BPLB) in infants and children with chronic liver disease (CLD). PATIENTS AND METHODS: BPLB was performed as an outpatient procedure using the aspiration Menghini technique in 80 infants and children, aged 2 months to 14 yrs, for diagnosis of their CLD. Patients were divided into three groups: Group 1 (<1 year), group 2 (1–6 yrs), and group 3 (6–14 yrs). The vital signs were closely monitored 1 hr before biopsy, and then 1, 2, 6, and 24 hrs after biopsy. Twenty-four hours pre- and post-biopsy complete blood counts, liver enzymes, prothrombin time (PT), and abdominal ultrasonography, searching for a biopsy-induced hematoma, were done for all patients. RESULTS: No mortality or major morbidities were encountered after BPLB. The rate of minor complications was 17.5% including irritability or “pain” requiring analgesia in 10%, mild fever in 5%, and drowsiness for >6 hrs due to oversedation in 2.5%. There was a statistically significant rise in the 1-hr post-biopsy mean heart and respiratory rates, but the rise was non-significant at 6 and 24 hrs except for group 2 where heart rate and respiratory rates significantly dropped at 24 hrs. No statistically significant difference was noted between the mean pre-biopsy and the 1, 6, and 24-hrs post-biopsy values of blood pressure in all groups. The 24-hrs post-biopsy mean hemoglobin and hematocrit showed a significant decrease, while the 24-hrs post-biopsy mean total leucocyte and platelet counts showed non-significant changes. The 24-hrs post-biopsy mean liver enzymes were non-significantly changed except the 24-hrs post-biopsy mean PT which was found to be significantly prolonged, for a yet unknown reason(s). CONCLUSIONS: Outpatient BPLB performed by the Menghini technique is safe and well tolerated even in infants and young children. Frequent, close monitoring of patients is strongly recommended to achieve optimal patient safety and avoid potential complications. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3271690/ /pubmed/22249089 http://dx.doi.org/10.4103/1319-3767.91735 Text en Copyright: © Saudi Journal of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
El-Shabrawi, Mortada H.
El-Karaksy, Hanaa M.
Okahsa, Sawsan H.
Kamal, Naglaa M.
El-Batran, Gamal
Badr, Khaled A.
Outpatient Blind Percutaneous Liver Biopsy in Infants and Children: Is it Safe?
title Outpatient Blind Percutaneous Liver Biopsy in Infants and Children: Is it Safe?
title_full Outpatient Blind Percutaneous Liver Biopsy in Infants and Children: Is it Safe?
title_fullStr Outpatient Blind Percutaneous Liver Biopsy in Infants and Children: Is it Safe?
title_full_unstemmed Outpatient Blind Percutaneous Liver Biopsy in Infants and Children: Is it Safe?
title_short Outpatient Blind Percutaneous Liver Biopsy in Infants and Children: Is it Safe?
title_sort outpatient blind percutaneous liver biopsy in infants and children: is it safe?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271690/
https://www.ncbi.nlm.nih.gov/pubmed/22249089
http://dx.doi.org/10.4103/1319-3767.91735
work_keys_str_mv AT elshabrawimortadah outpatientblindpercutaneousliverbiopsyininfantsandchildrenisitsafe
AT elkaraksyhanaam outpatientblindpercutaneousliverbiopsyininfantsandchildrenisitsafe
AT okahsasawsanh outpatientblindpercutaneousliverbiopsyininfantsandchildrenisitsafe
AT kamalnaglaam outpatientblindpercutaneousliverbiopsyininfantsandchildrenisitsafe
AT elbatrangamal outpatientblindpercutaneousliverbiopsyininfantsandchildrenisitsafe
AT badrkhaleda outpatientblindpercutaneousliverbiopsyininfantsandchildrenisitsafe